936749-56-3
物理化学性质
| 储存条件 | Store at -20°C, protect from light, stored under nitrogen |
| 溶解度 | DMSO: 260 mg/mL (746.53 mM); Water: 125 mg/mL (358.91 mM; ultrasonic and adjust pH to 10 with NaOH) |
| 形态 | Solid |
| 颜色 | White to off-white |
Cyclo(his-pro) (TFA)价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/08/19 | HY-101402A | Cyclo(his-pro) (TFA) Cyclo(his-pro) TFA | 936749-56-3 | 1 mg | 500元 |
| 2024/08/19 | HY-101402A | Cyclo(his-pro) (TFA) Cyclo(his-pro) TFA | 936749-56-3 | 10mM * 1mLin DMSO | 690元 |
| 2024/08/19 | HY-101402A | Cyclo(his-pro) (TFA) Cyclo(his-pro) TFA | 936749-56-3 | 5mg | 900元 |
常见问题列表
|
NF-κB
|
Human Endogenous Metabolite
|
Cyclo(his-pro) TFA (Cyclo(histidyl-proline) TFA; 50 μM; 1-48 hours) increases the nuclear level of Nrf2 and inhibits NF-κB nuclear translocation. Cyclo(His-Pro) alone has no effect on nuclear translocation of these transcription factors.
Cyclo(his-pro) TFA (50 μM; prior to PQ exposure for 48 hours) abolishes protein nitration that followed paraquat (PQ) exposure and lessenes its functional consequences, as shown by decrease in cell apoptosis, detected by caspase 3 activity and by cytochrome c release.
Cyclo(his-pro) TFA inhibits NF-κB nuclear accumulation induced by paraquat in rat pheochromocytoma PC12 cells via the Nrf2/heme oxygenase-1 pathway.
Western Blot Analysis
| Cell Line: | PC12 cells |
| Concentration: | 50 μM |
| Incubation Time: | 1, 2, 4, 8, 24, 48 hours |
| Result: | Increased the nuclear level of Nrf2 and inhibited NF-κB nuclear translocation. |
Cyclo(his-pro) TFA (Cyclo(histidyl-proline) TFA; 1.8 mg/ear; topical application on the right ear; 30 min prior to TPA) reduces TPA-induced ear oedema confirming that it can exert anti-inflammatory effect.
Cyclo(his-pro) TFA exerts in vivo anti-inflammatory effects in the central nervous system by down-regulating hepatic and cerebral TNFα expression thereby counteracting LPS-induced gliosis. Moreover, by up-regulating Bip, Cyclo(his-pro) increases the ER stress sensitivity andtriggers the unfolded protein response to alleviate the ER stress.
| Animal Model: | Sixty two/three month-old male C57BL/6 mice (25-30 g) |
| Dosage: | 1.8 mg/ear |
| Administration: | Topical application on the right ear; 30 min prior to TPA |
| Result: | Reduced TPA-induced ear oedema. |